AstraZeneca Licenses Three X-Chem Drug Discovery Programs

AstraZeneca is licensing three programs of X-Chem aimed at parsing out protein-protein interactions for oncology and respiratory/inflammation purposes. X-Chem is getting an up-front payment, as well as research funding, out of the deal.
Genetic Engineering & Biotechnology News